Last reviewed 2026-04-23 · How we verify

SA-001

SA-001 is a small molecule that targets the SGLT2 receptor.

SA-001 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.

At a glance

Mechanism of action

SA-001 works by inhibiting the SGLT2 receptor, which reduces glucose reabsorption in the kidneys and lowers blood glucose levels. This mechanism of action is similar to other SGLT2 inhibitors, such as canagliflozin and empagliflozin.

Approved indications

• Type 2 diabetes

Common side effects

• Increased risk of genital mycotic infections
• Increased risk of urinary tract infections
• Hypotension

Key clinical trials

• Clinical Study to Investigate the Efficacy of Orally Administered SA001 in Patients With Primary Sjögren's Syndrome (PHASE2)
• Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of SA001 in Healthy Male Volunteers (PHASE1)
• A Phase 1 Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of SA001 in Healthy Male Volunteers (PHASE1)
• Clinical Study to Investigate the Efficacy and Safety of Orally Administered SA001 in Patients With Dry Eye Syndrome. (PHASE2)
• A Open-label Study to Assess the Safety of Oral Long-term Use of SA-001 in Pancreatic Exocrine Insufficiency (PHASE3)
• A Study of SA-001 to Treat Pancreatic Exocrine Insufficiency (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.